Genmab A/S’s (GMAB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the stock.

GMAB has been the topic of several other reports. Citigroup lowered shares of Genmab A/S from a neutral rating to a sell rating in a research report on Monday, January 22nd. UBS Group upgraded Genmab A/S from a neutral rating to a buy rating in a research note on Wednesday, December 6th. BMO Capital Markets raised Genmab A/S from a market perform rating to an outperform rating and boosted their price target for the company from $46.00 to $48.00 in a research note on Friday, February 23rd. Morgan Stanley reiterated an underweight rating on shares of Genmab A/S in a research note on Tuesday. Finally, Truist Financial restated a buy rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $48.50.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $29.91 on Wednesday. Genmab A/S has a twelve month low of $26.32 and a twelve month high of $42.99. The stock has a market cap of $19.76 billion, a PE ratio of 31.16, a PEG ratio of 1.43 and a beta of 0.98. The firm has a 50-day simple moving average of $28.90 and a 200 day simple moving average of $31.08.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.02. The company had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. Research analysts forecast that Genmab A/S will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Several hedge funds have recently bought and sold shares of the stock. First Manhattan Co. bought a new position in shares of Genmab A/S in the 4th quarter valued at about $26,000. Headlands Technologies LLC bought a new position in shares of Genmab A/S during the third quarter valued at $27,000. Pinnacle Bancorp Inc. lifted its holdings in shares of Genmab A/S by 315.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after purchasing an additional 638 shares during the period. NBC Securities Inc. acquired a new stake in Genmab A/S in the third quarter valued at $37,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Genmab A/S by 86.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock worth $38,000 after purchasing an additional 498 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.